Skip to main navigation Skip to search Skip to main content

Pegylated interferon alpha-associated optic neuropathy

Research output: Contribution to journalArticlepeer-review

Abstract

A 52-year-old man with chronic hepatitis C presented with painless, bilateral, simultaneous nonarteritic anterior ischemic optic neuropathy (NAION) and peripheral neuropathy. Symptoms began 19 weeks after starting peginterferon alpha-2a. The peripheral neuropathy and vision of the right eye improved, but the vision of the left eye worsened after stopping interferon. We identified 23 additional cases of NAION during interferon alpha therapy. At least 12 of these patients suffered bilateral NAION. Patients lost vision 1-40 weeks after initiating therapy. Of 21 eyes that had documented initial and follow-up acuities, 8 improved, 1 worsened, and the rest remained stable. One patient had a painful peripheral neuropathy. Treatment with interferon alpha may result in NAION. Discontinuation of therapy deserves consideration after weighing individual risks and benefits.

Original languageEnglish (US)
Pages (from-to)117-122
Number of pages6
JournalJournal of Neuro-Ophthalmology
Volume30
Issue number2
DOIs
StatePublished - Jun 2010

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Pegylated interferon alpha-associated optic neuropathy'. Together they form a unique fingerprint.

Cite this